NEUROGENE INC (NGNE)
(Real Time Quote from BATS)
$39.24 USD
-32.29 (-45.14%)
Updated Nov 12, 2024 02:46 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NGNE 39.24 -32.29(-45.14%)
Will NGNE be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for NGNE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for NGNE
Neurogene Reports Promising Interim Results for NGN-401 Trial
Neurogene price target raised to $60 from $44 at Stifel
Neurogene price target raised by $16 at Stifel, here's why
Neurogene (NGNE) Receives a Buy from Stifel Nicolaus
Neurogene price target lowered to $60 from $65 at BMO Capital